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Materials and Methods

In vitro gastrointestinal dialysis model
Hymenocardine ( The mass spectrometer was operated in ESI+ mode at a resolution of 20000. Calibration was done externally and the following settings were applied: gas temperature 325°C, gas flow 7 L/min, nebulizer pressure 40 psi, sheath gas temperature 325°C, sheath gas flow 11 L/min.
Capillary, fragmentor, and skimmer voltages were set to 3500 V, 175 V, and 65 V, respectively, and the OCT 1 RF Vpp was set at 750 V. An MS scan was performed in the range of m/z 100 to 1000.
Incubation with liver S9 fraction
To investigate the formation of phase I metabolites of hymenocardine, reaction mixtures containing 420 μL 65 mM TRIS buffer (pH adjusted to 7.4 at 37°C), 25 μL human liver S9 fraction, and 5 μL hymenocardine (5 mM) were preincubated in triplicate in a shaking water bath at 37°C for 3 min. The reaction was initiated by the addition of 50 μL NADPH regenerating system and samples were incubated for 1 h at 37°C in a shaking water bath ( During a first analysis, full scan data were acquired using polarity switching with an m/z range of 70-1050 and resolving power set at 70000 at full width at half maximum (FWHM).
Spray voltage was set at ± 2.5 kV, sheath gas and auxiliary gas at 47 and 15 (adimensional), respectively, and capillary temperature at 350°C. Fragmentation data were also recorded using higher-energy collisional dissociation (HCD) and data dependent fragmentation (ddMS 2 ) in positive and negative ionization modes (one analysis per mode) to obtain additional structural information (resolving power set at 17500 FWHM, stepped collision energy 10, 30, 50 V, isolation window: 4 m/z, top 10 of most abundant ions selected for fragmentation). If fragmentation was not triggered due to low abundance of the metabolites, targeted MS 2 was carried out in an effort to get diagnostic product ion spectra.
SIEVE software for differential analysis and Xcalibur software (both from Thermo Fisher Scientific) were used for processing the raw data. The full scan data were processed in SIEVE to locate the metabolites that were formed: the software compares the metabolised hymenocardine data with the negative control data and method blanks, and filters out the differences. Subsequently, more structural information was obtained for the detected metabolites by examining the product ion spectra in both positive and negative ion modes (if available) ( Table S1 ). Software for drug metabolism prediction (Meteor Nexus version 2.1.0, Lhasa Limited) and Metaprint2D-React Web Server (University of Cambridge) were used to predict phase I metabolites from hymenocardine in silico. In Meteor, human metabolites (S9)
were predicted to a maximum depth of three levels. Redox and non-redox reactions were included and metabolites with a plausible or probable likelihood were taken into account. In Metaprint2D-React Web Server, default settings were used and also here, the human model was selected. The resulting list of in silico metabolites was matched with the list of metabolites retrieved from the S9 metabolisation experiments by linking the in silico metabolites with the most probable molecular formulae obtained with LC-HRMS. This resulted in 14 tentative metabolites.
